Previous 10 | Next 10 |
ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended June 30, 2022. First Quarter 2023 Financial Highlights: Revenue of $277 million, an increase of 10%, or 12% in consta...
Abiomed ( NASDAQ: ABMD ) is scheduled to announce FQ1 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $1.06 (-3.6% Y/Y) and the consensus Revenue Estimate is $276.46M (+9.4% Y/Y). Over the last 2 years, ABMD has beaten EPS ...
The middle of June marked a turning point for the stock market and new leadership has emerged for the recent run-up, according to Credit Suisse. Driving returns have been stocks that are Speculative (high correlation to Bitcoin ( BTC-USD )), Expensive (high P/E), Beaten Down (52...
Although the healthcare sector has largely resisted this year's downward pressure, it is likely to succumb as pressure increases. Healthcare stocks have a well-deserved reputation for cyclical defense, but they are more likely to underperform in "secular" bear markets. Healthcare ...
Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, August 4, 2022, the Company will release financial results for the first quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Thursday, August 4, 2022 at 8:00 a.m. ET. Michael R. ...
Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Last Friday was a stunning day for the market. The S&P 500 , Dow Jones Industrial Average and tech-heavy NASDAQ Composite ended the day up about 3.1%, 2.7% and 3.3%, respectively. For the week, the S&P 500, Dow...
Abiomed (NASDAQ:ABMD) announced that in August 2019 it had authorized the repurchase of up to $200M of the company’s common stock. Effective June 17, 2022, the company entered into a new 10b5-1 plan to continue repurchases under the program. The company most recently repurchased shares...
Abiomed, Inc . (NASDAQ: ABMD) today announced that it will host an investor call on the heart failure opportunity with the Impella 5.5 and future Impella BTR heart pumps on June 24, 2022 from 2:30 p.m. – 3:30 p.m. ET. The event will include presentations from heart failure sp...
Generation Investment Management's 13F portfolio value decreased from $24.33B to $21.84B this quarter. They increased Equifax, Clarivate Plc, Trane Technologies, Twilio, and Salesforce while reducing Dentsply Sirona & Sensata Technologies. The top three positions are Amazon.co...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...